|The CD90 (Thy 1.2) n/a (Catalog #MBS520244) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Anti-Mouse CD90 (Thy 1.2), APC (Clone 5a-8) (mouse IgG2b) reacts with Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s CD90 (Thy 1.2) can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC). Researchers should empirically determine the suitability of the CD90 (Thy 1.2) n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the Anti-Mouse CD90 (Thy 1.2), APC (Clone 5a-8) (mouse IgG2b) with the following immunoassay(s):
anti-mouse CD90 (Thy 1.2) is a monoclonal antibody that reacts with all T lymphocytes from mouse strains expressing the Thy 1.2 phenotype (e.g. C57BL/6, C3H/He, DBA/2, CBA/J, BALB/c, BXSB, NOD, NZB and SJL), but does not react with lymphocytes expressing the Thy 1.1 phenotype [e.g. AKR/J, B6.PL(74NS)].
Donor: AKR/J Spleen
Fusion Partner: Spleen from immunized recipient fused with myeloma P3-NSI-1-Ag4-1. Presentation: 100 ug APC conjugated Ig buffered in PBS, 0.1% NaN3 and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD90 (Thy 1.2) are readily searchable from our website. Different antibodies against the same target such as CD90 (Thy 1.2) may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.